Replication of the TECOS Diabetes Trial in Healthcare Claims
NCT03936062 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 349476
Last updated 2023-07-27
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
Interventions
- DRUG
-
Sitagliptin
Sitagliptin dispensing claim is used as the exposure
- DRUG
-
2nd generation sulfonylurea dispensing claim is used as the reference
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Womens
Eligibility
- Min Age
- 50 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-09-22
- Primary Completion
- 2021-02-18
- Completion
- 2021-02-18
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims
NCT06659744 ·Status: COMPLETED
-
Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims
NCT06659679 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
NCT01076075 ·Status: COMPLETED ·Phase: PHASE3
-
Emulation of the SOUL Diabetes Trial in Healthcare Claims
NCT06659718 ·Status: COMPLETED
-
Sitagliptin in Combination With Metformin and Sulfonylurea
NCT00686634 ·Status: COMPLETED ·Phase: PHASE4
-
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes
NCT00368134 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes
NCT00390520 ·Status: COMPLETED ·Phase: PHASE3
-
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)
NCT00509262 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
NCT00760344 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
NCT00313313 ·Status: COMPLETED ·Phase: PHASE3
-
Sotagliflozin Bioequivalence Study
NCT03211195 ·Status: COMPLETED ·Phase: PHASE1
-
Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)
NCT00704132 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes
NCT00661362 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
NCT00813995 ·Status: COMPLETED ·Phase: PHASE3
-
Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea
NCT03125694 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects
NCT03310944 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
NCT01338870 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control
NCT00698932 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy
NCT01169090 ·Status: COMPLETED ·Phase: PHASE2
-
Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)
NCT00106704 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
NCT02531035 ·Status: COMPLETED ·Phase: PHASE3
-
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
NCT01933672 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress
NCT00699322 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)
NCT00832624 ·Status: TERMINATED ·Phase: PHASE4
-
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
NCT01462266 ·Status: COMPLETED ·Phase: PHASE3